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Emerging data supports a role for negative wall remodeling in the failure of vascular interventions such as vein
grafts, yet clinicians/researchers currently lack the ability to temporally/efﬁciently investigate adventitial surface
topography/total vascular wall anatomy in vivo. We established a strategy of immobilizing commercially available
iron oxide magnetic nanoparticles (Fe-NPs) onto the surface of human vein conduits to facilitate high-throughput
total vascular wall demarcation with magnetic resonance (MR). Binding of activated Fe-NPs to amine groups on
the surface of the veins induced a thin layer of negative contrast that differentiated the adventitia from surrounding
saline signal in all MR images, enabling delineation of total wall anatomy; this was not possible in simultaneously
imaged unlabeled control veins. Under the conditions of this ex vivo experiment, stable covalent binding of
Fe-NPs can be achieved (dose-dependent) on human vein surface for MR detection, suggesting a potential strategy
for enhancing the ability of MRI to investigate total wall adaptation and remodeling in vein graft failure.
Over half a million vein grafts are implanted in the United
States each year, and yet the task of maintaining vein graft
patency continues to represent a major challenge for cardiac
and vascular clinicians. Almost 40% of lower extremity vein
bypass grafts develop occlusive lesions or fail within a year
(1), and almost half of cardiac bypass patients will lose (>75%
stenosis) a vein graft within the ﬁrst year (2). This manifests as
signiﬁcant morbidity and mortality for patients and contributes
to the enormous cost of cardiovascular health care related
expenses. For decades, researchers have sought to understand
the clinical, biological, and hemodynamic factors that contribute
to neointimal hyperplasia, the presumed primary pathophysi-
ology for early (1-18 months postimplantation) vein graft
failure. Vein wall thickening and neointimal hyperplasia develop
as an adaptive response to the arterial environment; luminal loss
seen directly with angiography, or indirectly as increased
velocity detected by duplex sonography, has traditionally been
viewed as a pathological dysregulation of this process. However,
with the increasing recognition of entire vessel wall negative
vein graft remodeling as a signiﬁcant contributor to vein graft
failure (3-6), there exists an opportunity and need for advances
in vascular imaging techniques to study total vein graft wall
adaptations and remodeling.
Magnetic resonance imaging (MRI) is a powerful noninvasive
diagnostic technique and a well-validated modality for vessel
wall (and surrounding soft tissue) imaging (7). However, it is
limited to modest spatial resolutions (e.g., 0.4 × 0.4 × 4m m 3)
that, while adequate to study atherosclerosis in medium to large
arteries, are largely inadequate for small-caliber vessels such
as human vein grafts (8). Even achieving such comparatively
high (by MR standards) spatial resolution poses a further
limitation with respect to attainable craniocaudal coverage. For
example, at clinical 1.5-3 T MRI magnetic ﬁeld strengths, a
10 min scan sufﬁces to image a 3-12 cm portion of a
vessel (8-10). Lower resolutions require less imaging time and
can enable increased coverage, but accurate delineation of the
anatomy of the tissue interfaces becomes increasingly difﬁcult
to achieve due to partial voluming of the different tissues (i.e.,
one voxel containing multiple tissues presents a signal intensity
that is the average of those of the underlying tissues).
One approach to overcome these challenges would be to coat
vein grafts with an implantable contrast agent at the time of
original surgical placement that can be readily identiﬁed by MRI,
thereby facilitating efﬁcient longitudinal imaging of the vessel
wall with reduced reliance on imaging resolution. Vein grafts
are often present on the operating room back table for up to
thirty minutes, a time that has been utilized for other graft wall
modiﬁcations (1). Superparamagnetic magnetic nanoparticles
(Fe-NPs) have been widely used as ultrasensitive negative
contrast agents for a wide range of applications such as stem
cell tracking and early detection of cancers (11-13). Over the
past decade, Fe-NPs have been explored for biomedical ap-
plications such as molecular imaging of cardiovascular disease,
gene delivery, magnetic drug targeting, nanomedicine, and
regenerative medicine (14, 15). These Fe-NPs provide an
attractive alternative to other commercially available contrast
agents because they are nontoxic and biocompatible, can
undergo selective magnetization only when exposed to a
magnetic ﬁeld, and also allow a targetable delivery with particle
localization in a speciﬁc area (16). Utilizing these advantages,
we have developed a method to attach Fe-NPs on the surface
of human veins, that can be performed under physiological
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adventitial label to facilitate and enhance MR imaging.
Previously, we have demonstrated that N-hydroxysuccinamide
esters of small target molecules could be covalently attached
to amine groups that are present on the cell surface (17). Human
mesenchymal stem cells modiﬁed through this method did not
alter the inherent cell properties such as cell viability, prolifera-
tion, adhesion kinetics, and their stem cell phenotype. This
suggests that covalent modiﬁcation could be performed under
conditions that have minimal impact on live cells. Thus, we
adopted a similar strategy to covalently immobilize Fe-NPs on
the surface of human veins. The current project capitalizes on
the innovative synergy of commercially available Fe-NPs
(modiﬁed to covalently bind to human tissue), and high spatial
resolution MRI to enhance visualization of the entire vessel wall
ex vivo. Speciﬁcally, we test the hypothesis that Fe-NPs can
be covalently immobilized onto the external wall of human vein
conduits and subsequently enable enhanced delineation of the
adventitia through MR imaging.
Amine groups are present in abundance on the surface of
various tissues (18) and are available to react with N-hydrox-
ysuccinamide. After appropriate institutional approvals, freshly
discarded human vein segments from bypass surgeries and major
amputations were collected and “labeled” with commercially
available Fe-NPs via a two-step reaction (Figure 1). Brieﬂy,
carboxylic groups that are on the magnetic nanoparticles’ surface
were activated by reacting with N-hydroxysuccinamide esters.
Subsequently, the activated particles were immediately used for
coating the vein graft adventitia. With the luminal side protected
via ligatures on either end, the test human vein sample was
placed in a PBS ﬁlled Petri dish. The activated magnetic particles
(in PBS) were added and incubated for 30 min at room
temperature (for detailed synthesis methods, see Supporting
Information). As a non-label control experiment, a vein segment
was incubated in PBS (without Fe-NPs). Finally, all vein
segments were individually and thoroughly rinsed thrice with
PBS to remove unbound Fe-NPs. The current technique was
applied with thirty minutes of incubation time, and this resulted
in signiﬁcant Fe-NP deposition on the vein; future optimization
of the reaction conditions (e.g., pH, temperature) may accelerate
this process.
Fe-NP labeled veins were thoroughly characterized using
scanning electron microscopy (SEM) and energy dispersive
X-ray analysis (EDAX). SEM images of labeled and unlabeled
veins clearly show the presence of Fe-NPs on the surface of
labeled veins (Figure 2). Results obtained from elemental
mapping analysis (SEM-EDAX) show that Fe-NP coatings
covered the majority of the labeled vein surface (Figure 3). In
addition, absence of Fe-NPs on the surface of unlabeled veins
was conﬁrmed (Figure 3). Iron histochemistry of labeled vein
cross sections, using Perl’s Prussian Blue protocol (see methods
in Supporting Information), was also performed to visualize the
location of Fe-NPs on the outer surface of the vein. Dark blue/
black stains in the polarized microscopy images are attributed
to the presence of Fe, suggesting that Fe is conﬁned to the vein
surface (Figure 4).
Prior to EDAX and histochemistry, MR imaging was
employed to validate our strategy of utilizing the magnetic
properties of Fe-NPs to readily delineate the vein surface from
any surrounding MR signal-generating environment. Vein
segments were immersed in saline to accomplish this task. Fe-
NPs create a large dipolar magnetic ﬁeld gradient that acts on
the water molecules that diffuse close to the particles (19). They
have a very large transverse to longitudinal relaxitivity ratio,
thus creating a predominant T2* effect resulting in MR signal
Figure 1. Schematic representation of the immobilization of Fe-NPs
on human vein. Incubation of the vein in an activated Fe-NPs solution
produces binding of Fe-NPs on its surface. Particles could bind to amine
groups on the cell surface as well as the extracellular matrix. Figure 2. SEM images of the outer surface of the human veins with
immobilized Fe-NPs (A and B) and without Fe-NPs (C and D).
Figure 3. SEM micrograph (left) and Fe elemental mapping using
EDAX (right) of unlabeled control (top row) and Fe-NPs labeled
(bottom row) surface of the human veins. EDAX was positive (colored)
for Fe on the Fe-NPs labeled portions only. In all images, scale bar
represents 20 µm.
Figure 4. Iron histochemistry. Perl’s Prussian blue staining images of
(A) Fe-NPs labeled and (B) unlabeled human veins. Presence of Fe is
conﬁrmed by the appearance of dark blue/black colored areas (shown
by red arrows in panel A).
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T1-, T2-, and T2*-weighted images (20).
T1-weighted (T1W), T2*-weighted (T2*W), and proton
density-weighted (PDW) high-resolution (spatial resolution 0.3
× 0.3 × 0.5 mm3) MR imaging of labeled and control vein
specimens was performed on a clinical 3 T MRI scanner (HDx,
General Electric, Milwaukee, WI) equipped with 40 mT/m
gradients (150 T/m/s slew rate) (Figure 5). For detailed MRI
methods, see Supporting Information. In addition, the MRI
dose-response to different Fe-NPs concentrations was explored:
four concentrations of Fe-NPs (50, 25, 12.5, and 6 µg) were
each mixed with a drop of Cyanoacrylate adhesive and placed
on the adventitia of an unlabeled vein prior to imaging. All three
vein segments were imaged simultaneously (Figure 5). Ad-
ditional experiments conﬁrmed that Cyanoacrylate adhesive had
no measurable effect for those image contrast weightings (not
shown).
Quantitative assessment of the ability of the Fe-NPs to
enhance delineation of the vein wall from surrounding signal
was performed by direct planimetry of the vessel wall and
surrounding signal voids caused by the Fe-NPs using region-
of-interest (ROI) measurements; for detailed methods, see
Supporting Information. In brief, three ROIs were drawn on
each of the control and labeled samples in T1W images: a central
ROI delineated the lumen, a second ROI delineated the outer
extent of the vein-wall tissue, and a third ROI was used to
delineate the region surrounding the vein. For the labeled vein,
this encompassed the outer extent of the iron oxide susceptibil-
ity-induced signal void. In the control vein segment, this region
was a similarly sized ROI containing some of the surrounding
saline around the control specimen (Figure 6). ROI areas were
used to deduce the average thickness of the vessel wall and
surrounding Fe-NP label, as well as the relative signal charac-
teristics of the vein wall tissue and label.
First, we tested the hypothesis that the vessel wall thickness
could be accurately measured despite the presence of the iron
oxide particles. The average wall thickness of the unlabeled
control vein segment was 1.47 ( 0.06 mm, while that of the
labeled segment was 1.36 ( 0.08 mm. The 0.11 mm difference
in wall thickness was statistically signiﬁcant (t-test, p < 0.0001).
There were no apparent trends in wall thickness with slice
location for either vein segment (Figure 7). Since both vein
segments were obtained from consecutive portions of the same
donor vein (1.5 cm length ea.), the observed difference in wall
thickness was most likely due to the signal nulling effect of the
Fe-NP on the labeled vein. This difference, however, is much
lower than in vivo MR imaging resolutions and thus is unlikely
to impact our ability to perform accurate wall thickness
measurements. At present, the highest published resolution used
for vein graft imaging is 0.312 mm in-plane (8-10), while most
in vivo MRI is performed at resolutions higher than 0.5 mm
due to scan time constraints at clinically used ﬁeld strengths of
1.5-3T .
A second analysis was performed to determine the ability of
the Fe-NP label to enhance the delineation of the vessel wall
boundary in comparison to the surrounding MR signal-generat-
ing environment. In general, this is a combination of the size
of the structure to be delineated (e.g., Fe-NP label) compared
to the image resolution, as well as the contrast to noise ratio of
the structure (e.g., imposed between the wall tissue and the Fe-
NP label).
For our ex vivo experiment, each of these two metrics was
assessed separately. The average thickness of the Fe-NP label
obtained from ROI measurements was 0.68 ( 0.17 mm (Figure
Figure 5. T1-weighted, T2*-weighted, and PD-weighted MR images
(0.3 × 0.3 × 0.5 mm3 resolution) obtained at3To fthree segments of
the same saphenous vein: a segment circumferentially labeled with
activated Fe-NPs as described in the text (top row); a segment with 4
equal drops of cyanoacrylate adhesive, each containing different
concentration of Fe-NPs (middle row); the unlabeled control vein
segment (bottom row). A sagittal curved multiplanar reformation of
the T1W acquisition is shown in the ﬁrst column; the dashed vertical
lines indicate the locations of the axial images shown in the other
columns. The concentration of Fe-NPs shown in the middle row of the
sagittal reformation is 6, 12.5, 25, and 50 µg, from left to right. All
vein segments were imaged immersed in Petri dishes ﬁlled with saline
and mounted on polystyrene scaffolds (white stars in images) to suspend
them within the ﬂuid.
Figure 6. Deﬁnition of ROIs and lengths used for quantitative analyses;
for each axial slice analyzed, a lumen ROI was ﬁrst delineated for both
the labeled and control segment. Next, a wall ROI was delineated for
both segments. Finally, a third ROI extending to the edge of the Fe-
NP label, or a corresponding similar region in the saline, was delineated
for the labeled and control vein specimens, respectively. These ROIs
were used to determine the average thickness of the vessel wall, the
average thickness of the Fe-NP label, and the CNR between vessel
wall and surrounding label or saline as appropriate. Finally, for the
dose-response experiment, the maximal width of the signal void was
measured for each axial slice along a line orthogonal to the vessel wall.
Figure 7. Average wall thickness of labeled and control vein segments
in each slice analyzed along the length of the specimens, and average
thickness of the iron-oxide susceptibility-induced signal void around
the labeled vein. Error bars indicate the standard deviation of measure-
ments across all slices.
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the CNR between the vessel wall and surrounding label was
20.3 ( 2.4. Such high CNR values observed with the Fe-NP
label are uncommon in vessel wall MRI; the highest CNR values
encountered are near 10, and represent signal differences
between the vessel wall and the signal void within the lumen
in black-blood MRI (21). CNRs are much lower between the
vessel wall and surrounding signal-generating tissues for in vivo
T1W vein graft imaging. Values near zero are often encountered
when the vein wall is surrounded by muscle or scar tissues.
Thus, the ﬁnding of this preliminary study is that the Fe-NP
label produces an effect that is global (encompassing the entire
vein wall irrespective of the surrounding signal) and that can
be readily detected (high CNR) within the limitations of current
in vivo MR imaging (extent greater than or equal to a single
pixel).
While multiplanar reformation of the vein segment with the
four concentrations of Fe-NP-loaded adhesive (50, 25, 12.5, and
6 µg) demonstrated a clear dose-response of the susceptibility-
induced signal void (Figure 5), a ﬁnal analysis was performed
to determine the correlation between Fe-NP concentration and
the thickness of the resulting label. As expected, there exists a
strong linear relationship between the width of the Fe-NP
susceptibility-induced signal void (Figure 6) and the iron oxide
load of the cyanoacrylate adhesive (Figure 8). Careful control
of the Fe-NP concentration will be critical, since at higher
concentrations (above 12.5 µg), the signal void induced by the
Fe-NPs interferes with visualization of the vein wall (Figure
5). Nonetheless, the linear response of the label to Fe-NP loading
suggests that this adverse effect can be minimized by optimiza-
tion of the reaction conditions to employ sufﬁciently low Fe-
NP quantities with which to label the vein wall.
An interesting effect observed in this study is underscored
by the “asymmetry” of the label thickness measurements in light
of the wall thickness difference between labeled and control
vein segments. Speciﬁcally, while the label measured nearly
0.7 mm thick, it only encroached 0.11 mm within the vessel
wall. This anisotropic effect of the Fe-NPs (namely, the
preferential nulling of signals outside the vessel wall rather than
equally affecting the vein wall tissue signal) is likely explained
by the increased mobility of the water protons in the saline
compared to those in the vessel wall. As a result, we can
postulate that in an in vivo environment the thickness of the
label will likely be lower at the same concentration. Nonetheless,
given current in vivo imaging resolutions and the large CNR
attainable by the Fe-NP label developed in this work, this study
suggests that sufﬁcient label thicknesses (g0.3 mm) can be
readily achieved to delineate the label without affecting
measurement of the vein wall tissue.
Data obtained from our ex vivo studies highlight the potential
application of Fe-NPs to enhance vein graft wall visualization
in vivo. By enhancing the sensitivity of MRIs to clearly delineate
the entire vessel wall, the relationship between vein wall
remodeling and early events (ﬁrst four weeks post implantation)
may eventually be investigated longitudinally and more ef-
ﬁciently. Such studies to date have required invasive imaging
techniques. External wall labeling with Fe-NPs may serve to
enhance the sensitivity of MRI by helping to more readily
delineate the vessel adventitia; this would be potentially useful
in the in vivo setting, where improving cranial caudal coverage
within clinical scan time remains a challenge. Since negative
wall remodeling (permanent constriction of the vein graft) stands
as an important etiology of failure (3-6), more sensitive
delineation of early negative remodeling may also enable timely
clinical interventions to halt the process.
The vein conduit labeling techniques can be expanded to
include other contrast agents such as gadolinium metal com-
plexes that can provide enhanced graft wall MR signals, thus
further improving the efﬁcacy and resolution of MRI as a tool
to investigate vein grafts (and other solid organ surfaces). On
the basis of these promising ex vivo results, we are in the process
of evaluating the stability and toxicity of this agent and strategy
using in vivo animal models. The potential long-term effects
of Fe-NPs localization on the surface of vein grafts, as well as
other distant organs such as liver and kidneys will be investi-
gated. The present strategy may also be combined with
molecular/biologically based contrast agents to provide a better
understanding of vascular wall remodeling mechanisms and
improve our understanding of vein graft failure.
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